Connect with us

Prescription Drugs

Could Johnson & Johnson Start Testing a Vaccine by Fall?

mm

Published

on

Johnson & Johnson, a major pharmaceutical company, has made plans to begin clinical trials on people of a vaccine for Covid-19 that it has developed. The company suggests it could be ready by September with the first batches of the vaccine ready for public use in an emergency early in 2021.

Hope for a Successful Vaccine

The company stated it had started work on a vaccine for the coronavirus early in January. It is working with BARDA, Biomedical Advance Research and Development Authority, which is a part of the Department of Health and Human Services. The two partners are committing $1 billion for research and development of the vaccine, along with testing.

The chairman of Johnson & Johnson, Alex Gorsky, says his company wants to do what they can to bring a vaccine to the public as quickly as possible. Manufacturing capacity around the world will be expanded if its approved to begin producing the vaccine immediately.

Early tests show the vaccine to be both safe and effective. The hope is that the partnership with BARDA will allow the vaccine to move through testing and approval faster. If approved, the vaccine would be distributed as not-for-profit.

Other Treatments and Vaccines

Another company has also been working on a vaccine. Moderna, a biotech firm based in the US, shipped a test vaccine to the government in February. The first dose has already been administered in a clinical trial in March. It uses material from DNA, which is injected into the body. Immune cells begin to make proteins that mark the virus cells for destruction.

Testing has also begun on a drug which could be used to treat patients with Covid-19. This drug, known as remdesivir, has been used in treatment of Ebola. It was given in a test to a patient who has Covid-19 and is the first drug to be tested for treatment. Other people who have tested positive for the virus will be part of the study.

The study will include volunteers who will either be given the drug or a placebo and monitored. The drug will be given intravenously over a ten-day period. Tests will be taken every other day to determine the amount of the virus in the system. If the drug shows some ability to prevent the growth of the virus, it could reduce the spread of Covid-19.

Experts warn the public not to rely on these early tests to make vaccines available right away. Even if they are viable, it’s expected that it could take at least a year before they would be readily available to the general public. Before this, specific people, such as medical care workers, may have access. Other methods will be necessary to control the spread of the disease in the meantime. However, a treatment for the disease may reduce the death rate. Researchers are working diligently to develop solutions to the coronavirus, but it’s not expected to see dramatic results overnight.

Comments

Prescription Drugs

Results from Remdesivir Clinical Trial to Come Soon

mm

Published

on

A clinical trial of remdesivir for treatment of coronavirus is expected to end in the next week or two with results to be available in the next two to three weeks. Remdesivir is an antiviral drug being tested to see the effectiveness against COVID-19.

Final results of the clinical trial are expected to be available by late May, but preliminary results may come in within one or two weeks. The first step will be analysis of the test, which will tell researchers if the drug performed better than the placebo.

Remdesivir was first tested as a possible treatment for another disease, Ebola. Researchers say it has shown promise for the treatment of the coronavirus in test tubes. Current information is conflicting as there are limitations on the knowledge available.

The Study

The current study is being conducted by the National Institutes of Health. It uses a placebo and is a double-blind trial with patients being chosen randomly. What this means is that all participants in the trial receive a treatment. It is either a dose of the drug or a placebo, but neither the patients or the doctors know who is getting remdesivir and who is getting the placebo.

The purpose for this kind of trial is to ensure the results are accurate and unbiased. They will be more believable for experts and the general public.

The target was to have 572 participants for the clinical trial, but researchers say they were over that goal. Participants came from all over the world. While the trial started with the University of Nebraska Medical Center, it has expanded to almost 70 other sites. There are sites in Germany, South Korea and many other places.

The hope is that the results will mean a big improvement for those who suffer from the virus. Researchers are hoping to see a shortening of the timeline for how long someone is sick as well as a reduction in the severity of symptoms. If the results don’t show what researchers hope for, they will remove it from the list of drugs and move onto another treatment for the next trial.

Previous Trials

Gilead Sciences is the maker of the drug, and it has completed its own testing. The company released information from the results of 53 patients, which indicated they had shown improvement after being given remdesivir. The manufacturer is encouraged by the results, but the trial is inconclusive because there was no secondgroup to act as the control group.

The World Health Organization published results from another trial with the same drug. In this trial, patients had severe symptoms from the virus. The summary showed that the drug didn’t have significant results in the treatment of the illness. However, the results were published accidentally and critics say that the trial was
terminated earlier than planned because fewer people had enrolled. Gilead stated that the study was inconclusive. Regardless of past trials and results, many people are waiting anxiously for the results of the current trial.

Comments
Continue Reading

Prescription Drugs

Testing Results for Antiviral Drug are Positive for COVID-19 Treatment

mm

Published

on

The antiviral drug remdesivir from Gilead Sciences shows positive preliminary results for treating the novel coronavirus. According to information from the manufacturer and others, the drug helps patients recover faster from the illness.

Hope for COVID-19 Patients

Data from the clinical trial shows that the medication cuts down the recovery time of patients, according to Dr. Fauci. The National Institute of Allergy and Infectious Diseases sponsored the study, which used a double-blind placebo trial to ensure the most accurate and unbiased results. Over 1000 patients were part of the study in many countries.

Even though the results have not been published, the information was announced, so that the placebo group could now have access to the drug since it showed evidence of working. The term recovery was defined to mean the patient was able to be discharged or return to their normal routine.

According to preliminary results, patients recovered 31 percent faster than those who received the placebo. This cut the time down from a median time of 15 days to 11 days. Early analysis indicates it may also lower the mortality rate, but the data must be analyzed completed to know for sure.

Fauci indicates the significance of the study isn’t just in how much recovery time improves, but in the fact that a drug can be effective for the virus. One of the doctors involved in the study explained another significance of the data. Time spent in the ICU causes stress on the body and increases the time needed for recovery. It’s important to have a drug that can decrease that time and hopefully lessen the impact the illness has on the body.

While researchers and many other experts are excited about the potential for remdesivir being the first drug capable of treating patients with COVID-19, the study must go through an in-depth analysis in a peer review. Even though no patients in the study showed evidence of serious side effects, the safety data hasn’t been received. This information is essential to determining how the medication would be used with the public.

Not a Cure All

Experts want people to understand that this drug isn’t a miracle drug to cure coronavirus. It works slowly in the system by preventing the illness from spreading. Other medical care is still necessary, especially for those who has suffered damage to organs from the virus. More studies are expected to begin which will combine remdesivir with other drugs to determine if they are more effective than using the drug alone.

A previous study done in China didn’t show improvement from use of the drug, but experts suggest it was because the study was stopped early due to not enough patients being recruited. The latest study offers hope to the public and researchers are cautiously optimistic about the impact it may have on treating COVID-19 going forward.

Other studies are in progress with various medications and vaccines are also being tested to prevent the virus in the future. It is expected that it may be another year before a vaccine is available for the general public.

Comments
Continue Reading

Prescription Drugs

Anti-parasite Drug Being Tested for Use Against COVID-19

mm

Published

on

The popular anti-parasite drug, ivermectin, is being tested to see if it is beneficial against COVID-19. This medication is often given for pinworm as well as nematode infections in humans. It can also be prescribed as a treatment for head lice. A version of the medication is also used as treatment of parasites in animals.

Hope for Treatment with COVID-19

The test hasn’t been performed on humans, but it was tested on a cell culture in a laboratory, which had been infected with COVID-19. The results showed that the viral colonies were reduced within two days by 5000 times.

The medication attaches to the nerve cells and muscles of parasites to cause paralysis and finally, death. The study was published in Antiviral Research and indicated the same medication has shown promise in limiting infection of other viruses. It may be used to treat influenza and West Nile virus.

While the medication targets roundworms with muscles and nerve cells, viruses don’t have these same cells to be targeted. However, they do contain a specific protein, which the ivermectin also targets.

The Benefits of Using Ivermectin with COVID-19

More testing is needed to determine if it can, in fact, help treat COVID-19. If testing is positive, it will provide several benefits for Americans. The drug is easily accessible because it’s listed as an essential medicine by the World Health Organization (WHO). The FDA has already approved it for humans back in 1996.

Ivermectin has already been determined to be safe for use in humans. On the other hand, it hasn’t been deemed as safe for pregnant women or in children under 33 pounds.

One of the risks with this medication is that it can increase the risk of bruising and bleeding if it is taken with Coumadin or warfarin. The most common side effects with the medication are fairly minor and include the following:

  • Nausea and vomiting
  • Abdominal pain
  • Constipation
  • Dizziness
  • Insomnia
  • Itching and rash

Side effects that are less common include swelling of the face, increased heart rate and low blood pressure.

The most popular use for ivermectin in the US is in animals. It is a commonly used treatment for parasitic worms in grazing animals, such as cattle. It’s also used for heartworm prevention in dogs and cats. It can also be used with some reptiles.

The research was conducted in Australia with the Biomedicine Discovery Institute from Monash University and Peter Doherty Institute of Infection and Immunity. According to the research, the coronavirus could be killed within 48 hours and significant improvement seen in 24 hours.

The next step, according to the researchers, is to find a dosage that is safe and effective in humans and test it on people. Since there isn’t an approved treatment for COVID-19 and a vaccine won’t be readily available for at least a year, researchers say it’s critical to find a current medication for treatment in a pandemic.

Even with positive testing, it can take some time for a drug like ivermectin to be used in a new treatment in the US.

Comments
Continue Reading

Trending